

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

-Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 703-308-4212; FAX: 703-308-4221

<u>Effective 12/13/03</u>: TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry directly to (EFFECTIVE 12/01/03):
 U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- 4 Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1803-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/03

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/050/365
ATTN: NEW RULES CASES	: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARI
Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retfieved in a word processor after creating it. Please adjust your right margin to 3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6Patentin 2.0 "bug"	A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentln would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 00/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
Patentin 2.0 "bug"	Please do not use "Copy to Disk" function of Patentln version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
3 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFWO

RAW SEQUENCE LISTING DATE: 11/21/2003 PATENT APPLICATION: US/10/650,365 TIME: 11:00:40

```
3 <110> APPLICANT: Wei, Guangwen
         Guo, Rongbing
 r,
         Zhang, Renhuai
 7 <120> TITLE OF INVENTION: Recombinant Super-Compound Interferon
 9 <130> FILE REFERENCE: 792-A-PCT-US
11 <140> CURRENT APPLICATION NUMBER: 10/650,365
12 <141> CURRENT FILING DATE: 2003-08-28
14 <150> PRIOR APPLICATION NUMBER: PCT/CN02/00128
15 <151> PRIOR FILING DATE: 2002-02-28
                                                                  Does Not Comply
                                         Invalid response, mary

Flease see item summary

Please see item summary

Sheet

tg ggt aac cgt core

au Gly Asn

)
17 <150> PRIOR APPLICATION NUMBER: CN 01104367.9
                                                                  Corrected Diskett Ne ded
18 <151> PRIOR FILING DATE: 2001-02-28
20 <160> NUMBER OF SEQ ID NOS: 13
22 <170> SOFTWARE: PatentIn version 3.2
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 504
26 <212> TYPE: DNA
27 <213> ORGANISM: human synthesis 30 <220> FEATURE:
31 <221> NAME/KEY: CDS
32 <222> LOCATION: (1)..(504)
34 <400> SEQUENCE: 1
35 atg tgc gac ctg ccg cag acc cac tcc ctg ggt aac cgt cgt gct ctg
36 Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu
                                         10
39 atc ctg ctg gct cag atg cgt cgt atc tcc ccg ttc tcc tgc ctg aaa
                                                                             96
40 Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys
                                     25
41
               20
43 gac cgt cac gac ttc ggt ttc ccg cag gaa gaa ttc gac ggt aac cag
                                                                            144
44 Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln
47 ttc cag aaa gct cag gct atc tcc gtt ctg cac gaa atg atc cag cag
                                                                            192
48 Phe Gln Lys Ala Gln Ala Tle Ser Val Leu His Glu Met Tle Gln Gln
       50
49
                            55
51 acc ttc aac ctg ttc tcc acc aaa gac tcc tcc gct gct tgg gac gaa
                                                                            240
52 Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu
                        70
                                             75
55 tee etg etg gaa aaa tie tae ace gaa etg tae eag eag etg aac gae
                                                                            288
56 Ser Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp
                   85
                                         90
59 ctg gaa got tgc gtt atc cag gaa gtt ggt gtt gaa gaa acc ccg ctg
                                                                            336
60 Leu Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu
61
               100
                                     105
                                                          110
63 atg aac gtt gac tee atc etg get gtt aaa aaa tae tte eag egt ate
                                                                            384
```

DATE: 11/21/2003

PATENT APPLICATION: US/10/650,365 TIME: 11:00:40 Input Set : A:\sequence listing.ST25.txt Output Set: N:\CRF4\11212003\J650365.raw 64 Met Asn Val Asp Scr Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile 120 67 acc ctg tac ctg acc gaa aaa aaa tac tcc ccg tgc gct tgg gaa gtt 432 68 Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val 135 71 gtt egt get gaa ate atg egt tee tte tee etg tee ace aac etg eag 480 72 Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln 73 145 150 Trualid response to item summer

Trualid response to item summer

The piease 10 operous sheet

The contract of 75 gaa cgt ctg cgt cgt aaa gaa taa 76 Glu Arg Leu Arg Arg Lys Glu 165 80 <210> SEQ ID NO: 2 81 <211> LENGTH: 167 82 <212> TYPE: PRT/ 83 <213> ORGANISM: human synthesi 85 <400> SEQUENCE: 2 87 Met Cys Asp Leu Pro Gln Thr His Scr Leu Gly Asn Arg Arg Ala Leu 1.0 91 Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys 20 25 95 Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln 35 40 99 Phe Gln Lys Ala Gln Ala Ile Ser Val Leu His Glu Met Ile Gln Gln 55 103 Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu 70 107 Ser Leu Leu Glu Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp 111 Leu Glu Ala Cys Val Ile Gln Glu Val Gly Val Glu Glu Thr Pro Leu 100 105 115 Met Asn Val Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Gln Arg Ile 115 120 119 Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val 135 140 123 Val Arg Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln 124 145 150 155 127 Glu Arg Leu Arg Arg Lys Glu)-Invalid response 128 131 <210> SEQ 1D NO: 3 132 <211> LENGTH: 360 133 <212> TYPE: DNA 134 <213> ORGANISM: (human synthesis 137 <220> FEATURE: 138 <221> NAME/KEY: CDS 139 <222> LOCATION: (1)..(360) 141 <400> SEQUENCE: 3 142 atg tgt gat tta cct caa act cat tct ctt ggt aac cgt cgc gct ctg 48 143 Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu

RAW SEQUENCE LISTING

144 1

RAW SEQUENCE LISTING DATE: 11/21/2003 PATENT APPLICATION: US/10/650,365 TIME: 11:00:40

	att Ile																96
	gac Asp																144
	ttc Phe																192
159 160		Phe	Asn	Leu	Phe	Ser 70	Thr	Lys	Asp	Ser	Ser 75	Ala	Ala	Trp	Asp	Glu 80	240
163 164	agc Ser	Leu	Leu	Glu	Lys 85	Phe	Tyr	Thr	Glu	Leu 90	Tyr	Gln	Gln	Leu	Asn 95	Asp	288
167 168	ctg Leu	Glu	Ala	Cys 100	Val	Ile	Gln	Glu									336
171 172	atg Met	Asn	Val 115	Asp	Ser												360
	<210																
	<211 <212				£U					^	0	err	10 M				
	<213				huma	an sy	int he	sis	1 -	SM	//	•					
				ICE:						_							
	Met	Cys	Asp	Leu		Gln	Thr	His	Ser	Leu	Gly	Asn	Arg	Arg	Ala	Leu	
182 183	Met 1				Pro 5					10					15		
182 183 186	Met			Ala	Pro 5				lle	10				Cys	15		
182 183 186 187	Met 1 Ile	Leu	Leu	Ala 20	Pro 5 Gln	Met	Arg	Arg	11e 25	10 Ser	Pro	Phe	Ser	Cys 30	15 Leu	Lys	
182 183 186 187 190	Met 1	Leu	Leu His	Ala 20	Pro 5 Gln	Met	Arg	Arg Pro	11e 25	10 Ser	Pro	Phe	Ser Asp	Cys 30	15 Leu	Lys	
182 183 186 187 190 191	Met 1 Ile Asp	Leu Arg	Leu His 35	Ala 20 Asp	Pro 5 Gln Phe	Met Gly	Arg Phe	Arg Pro 40	lle 25 Gln	10 Ser Glu	Pro Glu	Phe Phe	Ser Asp 45	Cys 30 Gly	15 Leu Asn	Lys Gln	
182 183 186 187 190 191	Met 1 Ile	Leu Arg	Leu His 35	Ala 20 Asp	Pro 5 Gln Phe	Met Gly	Arg Phe	Arg Pro 40	lle 25 Gln	10 Ser Glu	Pro Glu	Phe Phe Glu	Ser Asp 45	Cys 30 Gly	15 Leu Asn	Lys Gln	
182 183 186 187 190 191 194 195	Met 1 Ile Asp Phe	Leu Arg Gln 50	Leu His 35 Lys	Ala 20 Asp Ala	Pro 5 Gln Phe Gln	Met Gly Ala	Arg Phe Ile 55	Arg Pro 40 Ser	lle 25 Gln Val	10 Ser Glu Leu	Pro Glu His	Phe Phe Glu 60	Ser Asp 45 Met	Cys 30 Gly Ile	15 Leu Asn Gln	Lys Gln Gln	
182 183 186 187 190 191 194 195	Met 1 1le Asp Phe Thr	Leu Arg Gln 50	Leu His 35 Lys	Ala 20 Asp Ala	Pro 5 Gln Phe Gln	Met Gly Ala	Arg Phe Ile 55	Arg Pro 40 Ser	lle 25 Gln Val	10 Ser Glu Leu	Pro Glu His	Phe Phe Glu 60	Ser Asp 45 Met	Cys 30 Gly Ile	15 Leu Asn Gln	Lys Gln Gln	
182 183 186 187 190 191 194 195 198 199 202	Met 1 1le Asp Phe Thr	Leu Arg Gln 50 Phe	Leu His 35 Lys Asn	Ala 20 Asp Ala Leu	Pro 5 Gln Phe Gln Phe Lys	Met Gly Ala Ser 70	Arg Phe Ile 55 Thr	Arg Pro 40 Ser Lys	lle 25 Gln Val Asp	10 Ser Glu Leu Ser	Pro Glu His Ser 75	Phe Phe Glu 60 Ala	Ser Asp 45 Met	Cys 30 Gly Ile	15 Leu Asn Gln Asp	Lys Gln Gln Glu 80	
182 183 186 187 190 191 194 195 198 199 202 203	Met 1 1le Asp Phe Thr 65 Ser	Leu Arg Gln 50 Phe	Leu His 35 Lys Asn Leu	Ala 20 Asp Ala Leu Glu	Pro 5 Gln Phe Gln Phe Lys 85	Met Gly Ala Ser 70 Phe	Arg Phe Ile 55 Thr	Arg Pro 40 Ser Lys Thr	lle 25 Gln Val Asp	10 Ser Glu Leu Ser Leu 90	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln	Ser Asp 45 Met Ala Gln	Cys 30 Gly Ile Trp Leu	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206	Met 1 1le Asp Phe Thr 65	Leu Arg Gln 50 Phe	Leu His 35 Lys Asn Leu Ala	Ala 20 Asp Ala Leu Glu Cys	Pro 5 Gln Phe Gln Phe Lys 85 Val	Met Gly Ala Ser 70 Phe	Arg Phe Ile 55 Thr Tyr Gln	Arg Pro 40 Ser Lys Thr	lle 25 Gln Val Asp Glu Val	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207	Met l lle Asp Phe Thr 65 Ser Leu	Leu Arg Gln 50 Phe Leu Glu	Leu His 35 Lys Asn Leu Ala	Ala 20 Asp Ala Leu Glu Cys 100	Pro 5 Gln Phe Gln Phe Lys 85 Val	Met Gly Ala Ser 70 Phe Ile	Arg Phe Ile 55 Thr Tyr Gln	Arg Pro 40 Ser Lys Thr	lle 25 Gln Val Asp Glu Val	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210	Met 1 1le Asp Phe Thr 65 Ser	Leu Arg Gln 50 Phe Leu Glu	Leu His 35 Lys Asn Leu Ala Val	Ala 20 Asp Ala Leu Glu Cys 100	Pro 5 Gln Phe Gln Phe Lys 85 Val	Met Gly Ala Ser 70 Phe Ile	Arg Phe Ile 55 Thr Tyr Gln	Arg Pro 40 Ser Lys Thr Glu Ala	lle 25 Gln Val Asp Glu Val	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211	Met l lle Asp Phe Thr 65 Ser Leu Met	Leu Arg Gln 50 Phe Leu Glu Asn	Leu His 35 Lys Asn Leu Ala Val 115	Ala 20 Asp Ala Leu Glu Cys 100 Asp	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser	Met Gly Ala Ser 70 Phe Ile	Arg Phe Ile 55 Thr Tyr Gln	Arg Pro 40 Ser Lys Thr	lle 25 Gln Val Asp Glu Val	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211 214	Met 1 11e Asp Phe Thr 65 Ser Leu Met <210	Leu Arg Gln 50 Phe Leu Glu Asn	Leu His 35 Lys Asn Leu Ala Val 115	Ala 20 Asp Ala Leu Glu Cys 100 Asp	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser 5	Met Gly Ala Ser 70 Phe Ile Ile	Arg Phe Ile 55 Thr Tyr Gln Leu	Arg Pro 40 Ser Lys Thr Glu Ala 120	1le 25 Gln Val Asp Glu Val 105	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu Thr	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211 214	Met 1 11e Asp Phe Thr 65 Ser Leu Met <210	Leu Arg Gln 50 Phe Leu Glu Asn	Leu His 35 Lys Asn Leu Ala Val 115	Ala 20 Asp Ala Leu Glu Cys 100 Asp	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser 5	Met Gly Ala Ser 70 Phe Ile Ile	Arg Phe Ile 55 Thr Tyr Gln Leu	Arg Pro 40 Ser Lys Thr Glu Ala 120	1le 25 Gln Val Asp Glu Val 105	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu Thr	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211 214	Met 1 11e Asp Phe Thr 65 Ser Leu Met <210	Leu Arg Gln 50 Phe Leu Glu Asn	Leu His 35 Lys Asn Leu Ala Val 115	Ala 20 Asp Ala Leu Glu Cys 100 Asp	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser 5	Met Gly Ala Ser 70 Phe Ile Ile	Arg Phe Ile 55 Thr Tyr Gln Leu	Arg Pro 40 Ser Lys Thr Glu Ala 120	1le 25 Gln Val Asp Glu Val 105	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu Thr	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211 214 215 216 217 220	Met 1 1le Asp Phe Thr 65 Ser Leu Met <210 <211 <212 <213 <220	Leu Arg Gln 50 Phe Leu Glu Asn 0> SE > TY 8> OR 0> FE	Leu His 35 Lys Asn Leu Ala Val 115 CQ IC NGTH PE: GANI	Ala 20 Asp Ala Leu Glu Cys 100 Asp NO: 1: 10 DNA SM: (RE:	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser 5 8	Met Gly Ala Ser 70 Phe Ile Ile	Arg Phe Ile 55 Thr Tyr Gln Leu	Arg Pro 40 Ser Lys Thr Glu Ala 120	1le 25 Gln Val Asp Glu Val 105	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu Thr	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	
182 183 186 187 190 191 194 195 198 199 202 203 206 207 210 211 214 215 216 217 220 221	Met 1 11e Asp Phe Thr 65 Ser Leu Met <210	Leu Arg Gln 50 Phe Leu Glu Asn 0> SE > TY 8> OR 0> FE > NA	Leu His 35 Lys Asn Leu Ala Val 115 CQ IC CNGTH PE: CGANI CATUR ME/K	Ala 20 Asp Ala Leu Glu Cys 100 Asp NO: 1: 10 DNA SM: (EE:	Pro 5 Gln Phe Gln Phe Lys 85 Val Ser 5 8 Chem	Met Gly Ala Ser 70 Phe Ile Ile	Arg Phe Ile 55 Thr Tyr Gln Leu	Arg Pro 40 Ser Lys Thr Glu Ala 120	1le 25 Gln Val Asp Glu Val 105	10 Ser Glu Leu Ser Leu 90 Gly	Pro Glu His Ser 75 Tyr Val	Phe Phe Glu 60 Ala Gln Glu	Ser Asp 45 Met Ala Gln Glu	Cys 30 Gly Ile Trp Leu Thr	15 Leu Asn Gln Asp Asn 95	Lys Gln Glu 80 Asp	

DATE: 11/21/2003

```
TIME: 11:00:40
                PATENT APPLICATION: US/10/650,365
                Input Set : A:\sequence listing.ST25.txt
                Output Set: N:\CRF4\11212003\J650365.raw
224 <400> SEQUENCE: 5
225 alg tgc gac ctg ccg cag acc cac tcc ctg ggt aac cgt cgt gct ctg
                                                                          48
226 Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu
227 1
                                        10
229 atc ctg ctg gcl cag atg cgt cgt atc tcc ccg ttc tcc tgc ctg aaa
                                                                          96
230 Ile Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys
                                    25
233 gac cgt cac gac
                                                                         108
234 Asp Arg His Asp
235
            35
                                          -SAME Error
238 <210> SEQ ID NO: 6
239 <211> LENGTH: 36
240 <212> TYPE: PRT
241 <213> ORGANISM: (chemical synthesis
243 <400> SEQUENCE: 6
245 Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Asn Arg Arg Ala Leu
                                        10
249 Ilc Leu Leu Ala Gln Met Arg Arg Ile Ser Pro Phe Ser Cys Leu Lys
250
                2.0
                                    25
253 Asp Arg His Asp
254
            35
                                         rsame error
257 <210> SEQ ID NO: 7
258 <211> LENGTH: 107
259 <212> TYPE: DNA
260 <213> ORGANISM: / chemical systhesis
263 <220> FEATURE:
264 <221> NAME/KEY: Unsure
265 <222> LOCATION: (1)..(107)
267 <400> SEQUENCE: 7
268 ctgaaagacc gtcacgactt cggtttcccg caggagaggt tcgacggtaa ccagttccag
                                                                          60
                                                                         107
270 aageteagge tateteegtt etgeacgaaa tgateeagea gaeette
273 <210> SEQ ID NO: 8
                                         I same error
274 <211> LENGTH: 103
275 <212> TYPE: DNA
276 <213> ORGANISM:\ chemical systhesis
279 <220> FEATURE:
280 <221> NAME/KEY: Unsure
281 <222> LOCATION: (1)..(103)
283 <400> SEQUENCE: 8
284 gctgctggta cagttcggtg tagaattttt ccagcaggga ttcgtcccaa gcagcggagg
                                                                          60
                                                                         103
286 agtctttggt ggagaacagg ttgaaggtct gctggatcat ttc
289 <210> SEQ ID NO: 9
                                         -SAME Error
290 <211> LENGTH: 103
291 <212> TYPE: DNA
292 <213> ORGANISM: (chemical systhesis
295 <220> FEATURE:
296 <221> NAME/KEY: Unsure
297 <222> LOCATION: (1)..(103)
299 <400> SEQUENCE: 9
```

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING		DATE:	11/21/2003
PATENT APPLICATION:	US/10/650,365	TIME:	11:00:40

300 atccctgctg gaaaaattct acaccgaact gtaccagcag ctgaacgacc tggaagcttg 302 cgttatccag gaagttggtg ttgaagaaac cccgctgatg aac 305 <210> SEQ ID NO: 10 306 <211> LENGTH: 106 307 <212> TYPE: DNA 308 <213> ORGANISM: chemical synthesis	60 103
308 <213> ORGANISM: chemical synthesis 311 <220> FEATURE:	
312 <221> NAME/KEY: Unsure	
313 <222> LOCATION: (1)(106)	
315 <400> SEQUENCE: 10	
316 gaagaaaccc cgctgatgaa cgttgactcc atcctggctg ttaaaaaata cttccagcgt	60
318 atcaccetgt acetgacega aaaaaaatac teecegtgeg ettggg	106
321 <210> SEQ ID NO: 11	
322 <211> LENGTH: 112	
321 <210> SEQ 1D NO: 11 322 <211> LENGTH: 112 323 <212> TYPE: DNA 324 <213> ORGANISM chemical systhesis	
324 <213> ORGANISM chemical systhesis	
327 <220> FEATURE:	
328 <221> NAME/KEY: Unsure	
329 <222> LOCATION: (1)(112)	
331 <400> SEQUENCE: 11	60
332 ttattettta egaegeagae gtteetgeag gttggtggae agggagaagg aacgeatgat	60
334 ttcagcacga acaacttccc aagcgcacgg ggagtatttt ttttcggtca gg	112
337 <210> SEQ ID NO: 12	
339 <212> TYPE: DNA	
340 <213> ORGANISM: (chemical synthesis)	
338 <211> LENGTH: 31 339 <212> TYPE: DNA 340 <213> ORGANISM: Chemical synthesis 343 <220> FEATURE: 344 <221> NAME (NEW)	
344 <221> NAME/KEY: Unsure	
345 <222> LOCATION: (1)(31)	
347 <400> SEQUENCE: 12	
	31
348 atcggccata tgtgcgacct gccgcagacc c 351 <210> SEQ ID NO: 13 352 <211> LENGTH: 40 353 <212> TYPE: DNA 354 <213> ORGANISM: chemical synthesis	
352 <211> LENGTH: 40	
353 <212> TYPE: DNA	
357 <220> FEATURE:	
358 <221> NAME/KEY: Unsure	
359 <222> LOCATION: (1)(40)	
361 <400> SEQUENCE: 13	4.5
362 actgccagge tgcagttatt ctttacgacg cagacgttcc	40

VERIFICATION SUMMARYDATE: 11/21/2003PATENT APPLICATION: US/10/650,365TIME: 11:00:41